Skip to main content
Premium Trial:

Request an Annual Quote

Glaucus Proteomics To Rely On Dutch Supercomputing Brawn

NEW YORK, April 24-Glaucus Proteomics said today that it had struck agreements with SARA, the Dutch supercomputing center, and GigaPort, an Internet technology initiative funded by the Dutch government.

 

Glaucus intends to use the supercomputer center's muscle to characterize its collection of fully human antibodies, with the aim of developing antibody microarrays. The company also plans to identify biomarker patterns that can help fine-tune drug development.

 

Financial specifics were not disclosed.

 

Glaucus will have access to TERAS, a 1024 CPU system made up of two SGI Origin 3800 512 CPU systems with maximum 1 teraflop performance.

 

The company will connect to the facility via the GigaPort network, a broadband connection expected to provide10 gigabit/sec access.

 

Through this alliance, Glaucus will also have expert help with parallel code optimization, access to remote data backup, and remote help for in-house systems management.

 

Based in Utrecht, the Netherlands, Glaucus Proteomics is developing antibody and protein array technologies for drug development.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more